文章：

基于抗体的外周T细胞淋巴瘤治疗策略

Antibody-Based Therapies for Peripheral T-Cell Lymphoma

原文发布日期：15 October 2024

DOI: 10.3390/cancers16203489

类型: Article

开放获取: 是

英文摘要：

While antibody-based immunotherapeutic strategies have revolutionized the treatment of B-cell lymphomas, progress in T-cell lymphomas has suffered from suboptimal targets, disease heterogeneity, and limited effective treatment options. Nonetheless, recent advances in our understanding of T-cell biology, the identification of novel targets, and the emergence of new therapies provide hope for the future. In this review, we explore four areas of current and evolving antibody-based strategies for the treatment of peripheral T-cell lymphoma (PTCL): monoclonal antibodies (mAbs), bispecific antibodies (BsAs), chimeric antigen receptor T-cell therapy (CAR-T), and antibody–drug conjugates (ADCs). As part of this discussion, we will also include limitations, lessons learned, and potential future directions.

摘要翻译： 

尽管基于抗体的免疫治疗策略已彻底改变B细胞淋巴瘤的治疗格局，但在T细胞淋巴瘤领域，由于靶点选择欠佳、疾病异质性以及有效治疗方案有限，其进展一直较为缓慢。然而，近期在T细胞生物学认知、新型靶点发现及创新疗法涌现等方面取得的突破，为未来治疗带来了希望。本综述将围绕外周T细胞淋巴瘤（PTCL）的抗体治疗策略，从以下四个当前及发展中的方向展开探讨：单克隆抗体、双特异性抗体、嵌合抗原受体T细胞疗法以及抗体偶联药物。讨论中将涵盖现有局限、经验总结及未来潜在发展方向。

原文链接：

Antibody-Based Therapies for Peripheral T-Cell Lymphoma